Polymorphisms in Genes of Relevance for Oestrogen and Oxytocin Pathways and Risk of Barrett's Oesophagus and Oesophageal Adenocarcinoma: A Pooled Analysis from the BEACON Consortium

The strong male predominance in oesophageal adenocarcinoma (OAC) and Barrett's oesophagus (BO) continues to puzzle. Hormonal influence, e.g. oestrogen or oxytocin, might contribute. This genetic-epidemiological study pooled 14 studies from three continents, Australia, Europe, and North America....

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 10; no. 9; p. e0138738
Main Authors Lagergren, Katarina, Ek, Weronica E, Levine, David, Chow, Wong-Ho, Bernstein, Leslie, Casson, Alan G, Risch, Harvey A, Shaheen, Nicholas J, Bird, Nigel C, Reid, Brian J, Corley, Douglas A, Hardie, Laura J, Wu, Anna H, Fitzgerald, Rebecca C, Pharoah, Paul, Caldas, Carlos, Romero, Yvonne, Vaughan, Thomas L, MacGregor, Stuart, Whiteman, David, Westberg, Lars, Nyren, Olof, Lagergren, Jesper
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 2015
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The strong male predominance in oesophageal adenocarcinoma (OAC) and Barrett's oesophagus (BO) continues to puzzle. Hormonal influence, e.g. oestrogen or oxytocin, might contribute. This genetic-epidemiological study pooled 14 studies from three continents, Australia, Europe, and North America. Polymorphisms in 3 key genes coding for the oestrogen pathway (receptor alpha (ESR1), receptor beta (ESR2), and aromatase (CYP19A1)), and 3 key genes of the oxytocin pathway (the oxytocin receptor (OXTR), oxytocin protein (OXT), and cyclic ADP ribose hydrolase glycoprotein (CD38)), were analysed using a gene-based approach, versatile gene-based test association study (VEGAS). Among 1508 OAC patients, 2383 BO patients, and 2170 controls, genetic variants within ESR1 were associated with BO in males (p = 0.0058) and an increased risk of OAC and BO combined in males (p = 0.0023). Genetic variants within OXTR were associated with an increased risk of BO in both sexes combined (p = 0.0035) and in males (p = 0.0012). We followed up these suggestive findings in a further smaller data set, but found no replication. There were no significant associations between the other 4 genes studied and risk of OAC, BO, separately on in combination, in males and females combined or in males only. Genetic variants in the oestrogen receptor alpha and the oxytocin receptor may be associated with an increased risk of BO or OAC, but replication in other large samples are needed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Conceived and designed the experiments: KL WEE DL WC LB AC HR NJS NCB BJR DAC LJH AHW RCF PP CC YR TLV SMG DW LW ON JL. Performed the experiments: KL WEE DL WC LB AC HR NJS NCB BJR DAC LJH AHW RCF PP CC YR TLV SMG DW LW ON JL. Analyzed the data: WEE. Contributed reagents/materials/analysis tools: KL WEE DL WC LB AC HR NJS NCB BJR DAC LJH AHW RCF PP CC YR TLV SMG DW LW ON JL. Wrote the paper: KL WEE DL WC LB AC HR NJS NCB BJR DAC LJH AHW RCF PP CC YR TLV SMG DW LW ON JL.
Competing Interests: The authors have the following interests. The Romero Registry Consortium is supported in part by the Glaxo Wellcome Inc. Institute for Digestive Health “Clinical Research Award. The Romero Registry also has charitable gifts from five industry partners (Affymetrix, AstraZeneca, Santarus, Takeda and Wyeth.) The authors have received funding from commercial sources: Glaxo Wellcome Inc, Affymetrix, AstraZeneca, Santarus, Takeda and Wyeth, but these funding sources had no influence on the contents of the study. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0138738